STOCK TITAN
  1. Home
  2. News
  3. TPST

Tempest Therapeutics, Inc. - $TPST STOCK NEWS

Welcome to our dedicated page for Tempest Therapeutics news (Ticker: $TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tempest Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tempest Therapeutics's position in the market.

News
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) granted one employee a nonqualified stock option to purchase 7,650 shares of its common stock under the Company’s 2023 Inducement Plan. The stock option will vest over a four-year period, with 25% of the option vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) to participate in fireside chat at 35th Annual Piper Sandler Healthcare Conference. The company is a clinical-stage oncology company focusing on first-in-class therapeutics combining targeted and immune-mediated mechanisms. Management will be part of the discussion on November 28, 2023, at 3:00 p.m. ET. The live or archived recording can be accessed on the Tempest website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.25%
Tags
conferences
-
News
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
TPST - Tempest Therapeutics, Inc. reports superior results for TPST-1120 in liver cancer study, strengthening balance sheet. Multiple study endpoints showed promising results, including a 30% confirmed objective response rate and a median progression-free survival of 7 months for TPST-1120 arm. The company also plans to advance TPST-1120 into a registrational study and reported positive financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.31%
Tags
earnings
News
Tempest Adopts Limited Duration Stockholder Rights Plan
Rhea-AI Summary
Tempest Therapeutics adopts limited duration stockholder rights plan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3970.83%
Tags
none
-
News
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
Rhea-AI Summary
Tempest Therapeutics announces positive results from a Phase 1b/2 study of TPST-1120 in combination with atezolizumab + bevacizumab in the treatment of hepatocellular carcinoma (HCC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3970.83%
Tags
none
-
News
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Rhea-AI Summary
Tempest Therapeutics to report new data from Phase 1b/2 combination study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3970.83%
Tags
conferences
News
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
Rhea-AI Summary
Tempest Therapeutics announces expansion of role for executive VP and CMO, Sam Whiting, to include head of Research and Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
-
News
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Tempest Therapeutics to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
-
News
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Tempest Therapeutics, Inc. reported financial results for Q2 2023, including positive data from their TPST-1120 and TPST-1495 clinical programs. TPST-1120 demonstrated a 74.4% relative improvement in objective response rate (ORR) and a 69.9% relative improvement in confirmed ORR. TPST-1495 showed increased potency against prostaglandin-driven tumor models. The company expects to discuss updated data from the TPST-1120 trial in H2 2023 and report data from the TPST-1495 combination arm in 2024. Tempest ended Q2 with $17.6 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
earnings
News
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
Rhea-AI Summary
Tempest Therapeutics announces publication of in vitro and in vivo data on TPST-1495, a novel dual receptor inhibitor of prostaglandin E2 (PGE2) signaling. The data shows increased potency compared to existing drugs and supports previous clinical results of tumor shrinkage and disease control. Tempest also highlights their innovative pipeline, including TPST-1120 for first-line HCC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
Stock TPST logo
Tempest Therapeutics, Inc.

Nasdaq:TPST

TPST Rankings

#4560 Ranked by Market Cap
#91 Ranked by Stock Gains
N/A Ranked by Dividends

TPST Stock Data

70.65M
17.77M
3.16%
29.33%
4.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BRISBANE

About TPST

tempest therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. the molecules were developed by inception sciences, a versant ventures affiliated drug discovery engine. tempest has assembled a highly experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. tempest is backed by a syndicate of leading us and china based venture capital firms.